1. Recent experience with high-dose intravenous iron administration
D.A. Blaustein, M.H. Schwenk, J. Chattopadhyay, M.M. Avram 
Kidney International 
Volume 70, Pages S26-S29 (December 2006)
DOI: /sj.ki
Copyright © 2006 International Society of Nephrology Terms and Conditions

2. Figure 1
The hemoglobin concentrations (g/dl) in 29 patients at baseline, and at 1 month and 6 months after 2 daily 500mg doses of intravenous iron sucrose. P< for baseline vs 1 month post-dose and P< for baseline vs 6 months post-dose.
Kidney International  , S26-S29DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

3. Figure 2
The ferritin concentrations (ng/ml) in 29 patients at baseline, and at 1 month and 6 months after 2 daily 500mg doses of intravenous iron sucrose. P< for baseline vs 1 month post-dose and P< for baseline vs 6 months post-dose.
Kidney International  , S26-S29DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

4. Figure 3
The transferrin saturation (%) in 29 patients at baseline, and at 1 month and 6 months after 2 daily 500mg doses of intravenous iron sucrose. P< for baseline vs 1 month post-dose and P=0.01 for baseline vs 6 months post-dose.
Kidney International  , S26-S29DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions